Expertise in
17
conditions

Monia C. Marchetti

Alessandria, IT 
Expertise in
17
conditions
Alessandria, IT 

Overview

Monia Marchetti practices practicing medicine in Alessandria, Italy.

Ms. Marchetti is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Myelofibrosis, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 227 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

Alessandria, Italy
Other Locations
Sassari, Italy
Milan, Italy
Asti, Italy
Novara, Italy
Via Livornese Lato Monte, San Piero A Grado, Pisa, 56122, Italy
Reggio Nell'emilia, 40123, Italy
Massa, Italy
Turin, 10126, Italy
Perugia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other
Myeloproliferative Neoplasms (MPN) and COVID-19
Myeloproliferative Neoplasms (MPN) and COVID-19
Enrollment Status: Completed
Publish Date: September 15, 2025
Response Rate and Response Duration After Discontinuation of Treatment With Thrombopoietin Receptor Agonists in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study
Response Rate and Response Duration After Discontinuation of Treatment With Thrombopoietin Receptor Agonists in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).
A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia
Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia
Enrollment Status: Completed
Publish Date: October 06, 2020
Intervention Type: Drug
Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression
Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression
Enrollment Status: Completed
Publish Date: February 06, 2020
Intervention Type: Other
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Other
View 6 Less Clinical Trials

227 Total Publications

Management of inferior vena cava thrombosis: guidance from the Italian Society for the Study of Haemostasis and Thrombosis (SISET).
Management of inferior vena cava thrombosis: guidance from the Italian Society for the Study of Haemostasis and Thrombosis (SISET).
Journal: Thrombosis and haemostasis
Published: June 22, 2026

Frequently Asked Questions about Monia C. Marchetti

Is Monia C. Marchetti a top-rated expert for Myeloproliferative Neoplasms (MPN)?

MediFind is an objective health platform that identifies experts based on real-world data. Monia C. Marchetti is classified as an Distinguished expert for Myeloproliferative Neoplasms (MPN), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Monia C. Marchetti participate in research or clinical trials?

Yes. Monia C. Marchetti has published 227 articles and abstracts on conditions like Myeloproliferative Neoplasms (MPN). You can view a list of Monia C. Marchetti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Marchetti's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile